Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H30O2 |
Molecular Weight | 302.451 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@H](CC)[C@H](O)[C@@]1(C)CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4CC[C@@]23[H]
InChI
InChIKey=FCKLFGKATYPJPG-SSTBVEFVSA-N
InChI=1S/C20H30O2/c1-3-12-11-18-17-6-4-13-10-14(21)5-7-15(13)16(17)8-9-20(18,2)19(12)22/h10,12,15-19,22H,3-9,11H2,1-2H3/t12-,15-,16+,17+,18-,19-,20-/m0/s1
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/294104Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/2430141 and http://www.genome.jp/dbget-bin/www_bget?D01329
Sources: http://www.ncbi.nlm.nih.gov/pubmed/294104
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/2430141 and http://www.genome.jp/dbget-bin/www_bget?D01329
Oxendolone (brand name Prostetin; former name TSAA-291 is a steroidal antiandrogen and progestin of the 19-nortestosterone group that has been marketed in Japan by Takeda for the treatment of benign prostatic hyperplasia (BPH) since 1981. It is androgen receptor antagonist and it binds to progesterone receptor. It also acts as a weak but clinically relevant inhibitor of 5α-reductase. Oxendolone is approved for the treatment of BPH in Japan.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1871 Sources: http://www.genome.jp/dbget-bin/www_bget?D01329 |
320.0 nM [Ki] | ||
Target ID: CHEMBL208 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2430141 |
20.0 nM [Ki] | ||
Target ID: CHEMBL2096664 Sources: http://www.ncbi.nlm.nih.gov/pubmed/7292540 |
1.4 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Prostetin Approved UseIndications: prostatic hyperplasia |
PubMed
Title | Date | PubMed |
---|---|---|
Anti-androgen TSAA-291. VII. On the mechanism of anti-androgenic action of 16 beta-ethyl-17 beta-hydroxy-4-oestren-3-one (TSAA-291). | 1979 |
|
Anti-androgen TSAA-291. III. Hormonal spectra of anti-androgen TSAA-291 (16 beta-ethyl-17 beta-hydroxy-4-oestren-3-one) and its derivatives. | 1979 |
|
Effect of 16 beta-ethyl-17 beta-hydroxy-4-estren-3-one (TSAA-291) on the binding of promegestone (R5020) and methyltrienolone (R1881) to hyperplastic and neoplastic human prostate. | 1986 Sep |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6207714
i.m. injections of 400 mg oxendolone for 12 weeks
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7292540
Oxendolone inhibited 5-alpha-reductase activity in rat ventral prostates with IC 1.4uM
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL513856
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
m8300
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | Merck Index | ||
|
Oxendolone
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
3406
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
100000083037
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
443947
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
Y-11
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
33765-68-3
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
MN4I850D4P
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
4677
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
DTXSID8048814
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
C174717
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY | |||
|
SUB09514MIG
Created by
admin on Fri Dec 15 15:47:42 UTC 2023 , Edited by admin on Fri Dec 15 15:47:42 UTC 2023
|
PRIMARY |
ACTIVE MOIETY